AZN: AstraZeneca PLC - Summary | Jitta

AstraZeneca PLC

LON:AZN

Price
£111.66
Loss Chance
43.3%
6.85JITTA SCORE
12.05%Over Jitta Line
Jitta Ranking
797 / 1,214
Grow your money with Jitta Ranking. See details.
HISTORICAL JITTA SCORE
Jitta Factors
Growth Opportunity (82)
Recent Business Performance (82)
Financial Strength (76)
Return to Shareholders (60)
Competitive Advantage (75)
Jitta Signs
Revenue and EarningConsistent Growth in the past 5 years
Operating MarginConsistent
SG&A to SalesDecreasing
Recent Business PerformanceEarning decline 53.31% in the last quarter (yoy)
Cash Conversion CycleMore than 120 days
Key Stats
Jitta Score
Jitta Line
6.85
12.05%
3.03
59.12%
2.82
201.36%
Pharmaceuticals
3.83
17.93%
4.24
21.47%
5.40
79.33%
COMPANY DESCRIPTION
AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company’s marketed products include Calquence, Enhertu, Faslodex, Imfinzi, Iressa, Koselugo, Lumoxiti, Lynparza, Orpathys, Tagrisso, and Zoladex for oncology; Andexxa/Ondexxya, Atacand, Atacand HCT, Atacand Plus, Brilinta/Brilique, Bydureon/Byetta, BCise, Byetta, Crestor, Evrenzo, Farxiga/Forxiga, Komboglyze/Kombiglyze XR, Lokelma, Onglyza, Qtern, Xigduo/Xigduo, and Zestril XR for cardiovascular, renal, and metabolism diseases; Accolate, Accoleit, Vanticon, Bevespi Aerosphere, Breztri Aerosphere, Bricanyl Respules and Turbuhaler, Daliresp/Daxas, Duaklir Genuair, Fasenra, Pulmicort, Rhinocort, Saphnelo, Symbicort, and Tezspire for respiratory and immunology; and Kanuma, Soliris, Strensiq, and Ultomiris for rare diseases. Its marketed products also comprise Synagis for respiratory syncytial virus; Fluenz Tetra/FluMist Quadrivalent for Influenza; and Vaxzevria and Evusheld for covid-19. The company serves primary care and specialty care physicians through distributors and local representative offices in the United Kingdom, rest of Europe, the Americas, Asia, Africa, and Australasia. It has a collaboration agreement with Neurimmune AG to develop and commercialize NI006; and Personalis, Inc. The company was formerly known as Zeneca Group PLC and changed its name to AstraZeneca PLC in April 1999. AstraZeneca PLC was incorporated in 1992 and is headquartered in Cambridge, the United Kingdom.